Blizard Institute, Queen Mary, University of London, London, UK.
Department of Infectious Diseases, Imperial College London, London, UK.
Thorax. 2017 Sep;72(9):850-852. doi: 10.1136/thoraxjnl-2016-209841. Epub 2017 Feb 16.
WHO recently recommended the use of a shorter multidrug-resistant TB (MDR-TB) regimen under programmatic conditions. We assessed eligibility for this regimen in a cohort of 737 adult patients with MDR-TB from Latvia, Lithuania, Estonia and Bucharest city recruited in 2007 and 2009. Only 4.2% of the patients were eligible for this regimen. Ethambutol (64%), pyrazinamide resistance (58%) and previous exposure to second-line TB drugs were major reasons for non-eligibility. High-level resistance to isoniazid is expected due to widespread prevalence of mutations. In Eastern Europe, the use of the shorter regimen might be an exception rather than a rule.
世卫组织最近建议在规划条件下使用更短的耐多药结核病（MDR-TB）方案。我们在 2007 年和 2009 年招募的来自拉脱维亚、立陶宛、爱沙尼亚和布加勒斯特的 737 名耐多药结核病成人患者队列中评估了该方案的适用性。只有 4.2%的患者符合该方案的条件。乙胺丁醇（64%）、吡嗪酰胺耐药（58%）和以前接触二线结核病药物是不合格的主要原因。由于突变的广泛流行，预计异烟肼的高水平耐药是不可避免的。在东欧，使用更短的方案可能是例外情况，而不是常规情况。
